Foaming Agents for Drug Delivery to Treat Inflammatory Bowel Disease Abstract:About 1.6 million Americans suffer from Inflammatory Bowel Disease (IBD), a condition that includes Crohn’s Disease and Ulcerative Colitis (2). Treatment of this condition focuses on reducing the inflammation caused by IBD either through anti inflammatory drugs or immunosuppressants (4). Many times it is preferable to deliver these drugs topically, and foams provide several benefits over the common liquid enemas (as noted in Malchow 2002)(3), Furthermore, several foam products are already on the market to treat colitis including foams containing Mesalazine and Budesonide (1). Our experiment focuses on formulating an optimal foaming solution for lower intestinal tract drug delivery. In addition to clinical treatment, we hope these foams will help researchers test new therapies for IBD and other disorders affecting the lower gastrointestinal tract.For our research, we tested solutions containing PEG or alginate and two foaming agent...